11 results
8-K
EX-99.1
PROK
ProKidney Corp - Ordinary Shares
26 Jan 24
Regulation FD Disclosure
12:00am
subjects excluded due to eGFR ACR eGFR ACR - -n- - Deferred Cohort SOC 29.1 1395 -- -- attrition during SOC Deferred Cohort post injection -- -- 20.8
424B3
PROK
ProKidney Corp - Ordinary Shares
21 Apr 23
Prospectus supplement
4:18pm
are completed. There is typically an extremely high rate of attrition from the failure of product candidates proceeding through clinical trials. Product
POS AM
PROK
ProKidney Corp - Ordinary Shares
17 Apr 23
Prospectus update (post-effective amendment)
5:01pm
trials may not be indicative of results obtained when such trials are completed. There is typically an extremely high rate of attrition from the failure
424B3
PROK
ProKidney Corp - Ordinary Shares
9 Sep 22
Prospectus supplement
5:05pm
of results obtained when such trials are completed. There is typically an extremely high rate of attrition from the failure of product candidates
DEFM14A
6ldp0s3j7n
10 Jun 22
Proxy related to merger
4:54pm
PRER14A
cmj0dw9z 2e25
11 Apr 22
Preliminary revised proxy
5:29pm
PREM14A
adidwc
14 Feb 22
Preliminary proxy related to merger
4:55pm
- Prev
- 1
- Next